<DOC>
	<DOCNO>NCT01334255</DOCNO>
	<brief_summary>LT1009-Oph-002 Phase 1b study design evaluate safety potential efficacy iSONEP follow one , two three injection iSONEP , need , treatment Pigment Epithelial Detachment ( PED ) secondary PED Secondary Exudative Age-Related Macular Degeneration ( AMD ) Polypoidal Choroidal Vasculopathy ( PCV ) .</brief_summary>
	<brief_title>iSONEP Treat Persistent Pigment Epithelial Detachment ( PED ) Subjects With Exudative Age-Related Macular Degeneration ( AMD ) Polypoidal Choroidal Vasculopathy ( PCV )</brief_title>
	<detailed_description>Sixteen ( 16 ) subject per dose group receive minimum 3 7 dos anti-VEGF agent ( i.e. , Lucentis Avastin ) , whose PED decrease great 25 % height despite therapy , enrol total 32 subject . The presence PED diagnose Investigator confirm SDOCT , ICG FA digital image reading center prior subject enrollment . The ability iSONEP induce regression persistent PED subject exudative AMD PCV despite previous treatment anti-VEGF agent evaluate .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<criteria>Males female &gt; 50 year age diagnosis PED secondary AMD PCV Serous and/or fibrovascular PED secondary exudative AMD secondary PCV ( confirm SDOCT , FA ICG ) demonstrate least 25 % decrease height PED ( onset antiVEGF therapy ) follow minimum 3 dos antiVEGF agent ( i.e. , Lucentis Avastin ) PED height great 100 Î¼m Presence CNV secondary ( ) AMD ( base FA ) ( ii ) PCV ( base ICG ) ETDRS BCVA 20/32 20/320 ( letter score 73 25 ) study eye ETDRS visual acuity 20/400 good fellow eye Subjects previously treat , currently receive treatment another investigational agent device neovascular AMD study eye Subjects receive &lt; 3 &gt; 7 antiVEGF treatment study eye Subjects retinal angiomatous proliferation ( RAP lesion ) Lucentis Avastin within 30 day prior Day 1 study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Pigment epithelial detachment</keyword>
	<keyword>Exudative age-related macular degeneration</keyword>
	<keyword>Polypoidal choroidal vasculopathy</keyword>
</DOC>